BR0207761A - Uso de um vìrus leporipox recombinante vivo, vacina, e, vìrus leporipox recombinante vivo - Google Patents
Uso de um vìrus leporipox recombinante vivo, vacina, e, vìrus leporipox recombinante vivoInfo
- Publication number
- BR0207761A BR0207761A BR0207761-2A BR0207761A BR0207761A BR 0207761 A BR0207761 A BR 0207761A BR 0207761 A BR0207761 A BR 0207761A BR 0207761 A BR0207761 A BR 0207761A
- Authority
- BR
- Brazil
- Prior art keywords
- leporipox virus
- recombinant leporipox
- virus
- live recombinant
- lepori
- Prior art date
Links
- 241000700563 Leporipoxvirus Species 0.000 title abstract 8
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 108091029865 Exogenous DNA Proteins 0.000 abstract 3
- 230000001717 pathogenic effect Effects 0.000 abstract 2
- 230000003612 virological effect Effects 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000009851 immunogenic response Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
- 229940126580 vector vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
"USO DE UM VìRUS LEPORIPOX RECOMBINANTE VIVO, VACINA, E, VìRUS LEPORIPOX RECOMBINANTE VIVO". A presente invenção é direcionada ao uso de um vírus leporipox recombinante vivo, que compreende DNA exógeno que é operavelmente ligado a pelo menos um elemento de controle da expressão e que é incorporado em uma região não essencial do genoma viral, na fabricação de uma vacina vetorial para o tratamento e/ou profilaxia de doenças infecciosas em espécies não lepori. A invenção além disso diz respeito a um vírus leporipox recombinante vivo compreendendo DNA exógeno operavelmente ligado a pelo menos um elemento de controla de expressão e incorporado em uma região nao essencial do genoma viral caracterizado em que referido DNA exógeno codifica pelo menos um antígeno de um patógeno não lepori. Por causa de sua faixa restrita de hospedeiros, o vírus leporipox recombinante é não patogênico pelo menos em hospedeiros não suscetiveis, tais como os vertebrados não lepori. A vacinação com referido vírus leporipox recombinante induziu uma resposta antigênica ou imunogênica no hospedeiro não lepori vacinado, não obstante a replicação produtiva do vírus não tenha sido observada no hospedeiro.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01200869 | 2001-03-08 | ||
| PCT/EP2002/002858 WO2002072852A2 (en) | 2001-03-08 | 2002-03-07 | Leporipox-based vector vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0207761A true BR0207761A (pt) | 2006-01-31 |
Family
ID=8179978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0207761-2A BR0207761A (pt) | 2001-03-08 | 2002-03-07 | Uso de um vìrus leporipox recombinante vivo, vacina, e, vìrus leporipox recombinante vivo |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6942864B2 (pt) |
| EP (1) | EP1370668B1 (pt) |
| JP (1) | JP4037273B2 (pt) |
| CN (1) | CN1258596C (pt) |
| AT (1) | ATE318321T1 (pt) |
| AU (1) | AU2002304856B2 (pt) |
| BR (1) | BR0207761A (pt) |
| CA (1) | CA2439872C (pt) |
| DE (1) | DE60209345T2 (pt) |
| DK (1) | DK1370668T3 (pt) |
| ES (1) | ES2258628T3 (pt) |
| MX (1) | MXPA03007862A (pt) |
| NO (1) | NO331305B1 (pt) |
| NZ (1) | NZ527940A (pt) |
| PT (1) | PT1370668E (pt) |
| WO (1) | WO2002072852A2 (pt) |
| ZA (1) | ZA200306607B (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090014364A (ko) * | 2006-06-01 | 2009-02-10 | 로바츠 리서치 인스티튜트 | 암 치료용 점액종 바이러스 변이종 |
| KR100831536B1 (ko) * | 2007-01-19 | 2008-05-22 | 리엔 창 일렉트로닉 엔터프라이즈 컴퍼니 리미티드 | 풀 브릿지 드라이버 |
| KR100831537B1 (ko) * | 2007-01-19 | 2008-05-22 | 리엔 창 일렉트로닉 엔터프라이즈 컴퍼니 리미티드 | 하프 브릿지 드라이버 |
| FR2925067B1 (fr) * | 2007-12-18 | 2010-01-15 | Agronomique Inst Nat Rech | Vecteurs vaccinaux derives de leporipoxvirus |
| US20230151387A1 (en) * | 2020-04-02 | 2023-05-18 | Arizona Board Of Regents On Behalf Of Arizona State University | Covid-19 vaccine based on the myxoma virus platform |
| CN111904981A (zh) * | 2020-09-07 | 2020-11-10 | 威世药业（如皋）有限公司 | 一种痘苗病毒致炎兔皮生产方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5174993A (en) * | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
| US5505941A (en) * | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
| US5833975A (en) * | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| DE10399032I1 (de) * | 1987-08-28 | 2004-01-29 | Health Research Inc | Rekombinante Viren. |
| WO1993001284A1 (en) | 1991-07-09 | 1993-01-21 | Cornell Research Foundation, Inc. | Recombinant viral vaccine |
| TW377373B (en) | 1993-09-22 | 1999-12-21 | Wyeth Corp | Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease |
| US6001349A (en) * | 1995-02-22 | 1999-12-14 | Therion Biologics Corporation | Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof |
| FR2736358B1 (fr) | 1995-07-05 | 1997-09-26 | Agronomique Inst Nat Rech | Virus myxomateux recombinant |
| AU4266597A (en) * | 1996-09-11 | 1998-04-14 | General Hospital Corporation, The | Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell |
| US6127172A (en) | 1998-05-29 | 2000-10-03 | University Of Florida | Materials and methods for delivery and expression of heterologous DNA in vertebrate cells |
| ES2153284B1 (es) | 1998-06-10 | 2001-09-01 | Fundacion Para El Estudio Y De | Nuevo virus recombinante de mixoma atenuado y su uso en la preparacion de vacunas mixtas contra la mixomatosis y la enfermedad hemorragica de los conejos. |
| US6294176B1 (en) * | 1998-07-10 | 2001-09-25 | Schering-Plough Veterinary Corp. | Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species |
-
2002
- 2002-03-07 MX MXPA03007862A patent/MXPA03007862A/es active IP Right Grant
- 2002-03-07 CA CA002439872A patent/CA2439872C/en not_active Expired - Fee Related
- 2002-03-07 ES ES02732485T patent/ES2258628T3/es not_active Expired - Lifetime
- 2002-03-07 BR BR0207761-2A patent/BR0207761A/pt not_active IP Right Cessation
- 2002-03-07 NZ NZ527940A patent/NZ527940A/en not_active IP Right Cessation
- 2002-03-07 CN CN02806102.0A patent/CN1258596C/zh not_active Expired - Fee Related
- 2002-03-07 PT PT02732485T patent/PT1370668E/pt unknown
- 2002-03-07 AU AU2002304856A patent/AU2002304856B2/en not_active Ceased
- 2002-03-07 EP EP02732485A patent/EP1370668B1/en not_active Expired - Lifetime
- 2002-03-07 DK DK02732485T patent/DK1370668T3/da active
- 2002-03-07 US US10/471,300 patent/US6942864B2/en not_active Expired - Fee Related
- 2002-03-07 JP JP2002571903A patent/JP4037273B2/ja not_active Expired - Fee Related
- 2002-03-07 AT AT02732485T patent/ATE318321T1/de not_active IP Right Cessation
- 2002-03-07 WO PCT/EP2002/002858 patent/WO2002072852A2/en active IP Right Grant
- 2002-03-07 DE DE60209345T patent/DE60209345T2/de not_active Expired - Lifetime
-
2003
- 2003-08-25 ZA ZA2003/06607A patent/ZA200306607B/en unknown
- 2003-09-04 NO NO20033912A patent/NO331305B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE318321T1 (de) | 2006-03-15 |
| JP4037273B2 (ja) | 2008-01-23 |
| NZ527940A (en) | 2005-01-28 |
| WO2002072852A2 (en) | 2002-09-19 |
| US6942864B2 (en) | 2005-09-13 |
| CA2439872A1 (en) | 2002-09-19 |
| CN1258596C (zh) | 2006-06-07 |
| CN1527883A (zh) | 2004-09-08 |
| PT1370668E (pt) | 2006-06-30 |
| CA2439872C (en) | 2009-12-15 |
| NO331305B1 (no) | 2011-11-21 |
| NO20033912L (no) | 2003-10-22 |
| DE60209345D1 (de) | 2006-04-27 |
| AU2002304856B2 (en) | 2006-08-24 |
| DK1370668T3 (da) | 2006-06-06 |
| ES2258628T3 (es) | 2006-09-01 |
| MXPA03007862A (es) | 2004-05-24 |
| EP1370668A2 (en) | 2003-12-17 |
| WO2002072852A3 (en) | 2002-12-27 |
| EP1370668B1 (en) | 2006-02-22 |
| DE60209345T2 (de) | 2006-08-03 |
| ZA200306607B (en) | 2005-02-23 |
| JP2004528833A (ja) | 2004-09-24 |
| US20040137599A1 (en) | 2004-07-15 |
| NO20033912D0 (no) | 2003-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022014808A2 (pt) | Composições e métodos para vacinas para prevenir e tratar infecção pelo coronavírus-sars-cov-2 | |
| BRPI0408623A (pt) | conjugados de partìcula semelhante ao vìrus análogo de peptìdeo de melan-a | |
| Chaung et al. | Salmonella flagellin enhances mucosal immunity of avian influenza vaccine in chickens | |
| CY1115749T1 (el) | Κυκλοϊος χοιρων, νουκλεϊνικα οξεα, πολυπεπτιδια και εμβολια | |
| CY1106848T1 (el) | Τροποποιημενος ιος vaccinia ankara για τον εμβολιασμο νεογνων | |
| CY1110585T1 (el) | ΣΥΣΚΕΥΑΣΙΑ (ΠΑΚΕΤΑΡΙΣΜΑ) ΑΝΟΣΟΔΙΕΓΕΡΤIΚΩΝ CpG ΕΝΤΟΣ ΟΜΟΙΑΖΟΝΤΩΝ ΜΕ ΙΟ ΣΩΜΑΤΙΩΝ: ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΚΑΙ ΧΡΗΣΗ | |
| BR0114393A (pt) | Uso de uma preparação de vìrus envelopado dividido, método para produzir uma formulação de vacina intranasal, uso de uma preparação de vacina de vìrus envolopado dividido, kit para liberação de uma formulação de vacina intranasal, dispositivo de liberação intranasal, e, método para proteger ou tratar um mamìfero susceptìvel a, ou sofrendo de doença causada por vìrus envelopado | |
| EA200900180A1 (ru) | Рекомбинантный модифицированный вирус осповакцины анкара (mva), экспрессирующий гомологичные последовательности, встроенные в поксвирусный геном | |
| RU94038050A (ru) | Рекомбинантный вирус, вектор, вакцина, способ иммунизации, клетка-хозяин | |
| BRPI0711608B8 (pt) | composição liofilizada, uso de antígeno viral, método de tratamento ou prevenção de vírus associado, método de adaptação de um vírus de uma linhagem celular adequada | |
| BR0312474A (pt) | Partìcula viral adjuvante | |
| CY1118573T1 (el) | Χρηση ενος τροποποιημενου ιου ευλογιας για την ταχεια επαγωγη ανοσιας εναντι ενος ιου ευλογιας ή αλλων μολυσματικων παραγοντων | |
| BR0207761A (pt) | Uso de um vìrus leporipox recombinante vivo, vacina, e, vìrus leporipox recombinante vivo | |
| BR0316291A (pt) | Vacina contra hcv, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina contra hcv | |
| MX2022010588A (es) | Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2. | |
| AR094725A1 (es) | Parvovirus 5a porcino, métodos de uso y vacuna | |
| Yogisharadhya et al. | Functional characterization of recombinant major envelope protein (rB2L) of orf virus | |
| BR112022000710A2 (pt) | Vacina viral terapêutica | |
| WO2003078640A8 (en) | Recombinant drug-sensitive vaccinia virus as smallpox vaccine | |
| Yuan et al. | DNA vaccination with a gene encoding VP60 elicited protective immunity against rabbit hemorrhagic disease virus | |
| CN108367066B (zh) | 包括类病毒颗粒及新型佐剂的禽流感疫苗组合物 | |
| CO2023005978A2 (es) | Hvt recombinante y usos de este | |
| ATE450270T1 (de) | Impstoff gegen mikrobielle pathogenen | |
| AR027443A1 (es) | MUTANTES DE EHV gM-NEGATIVOS | |
| CA2366056A1 (en) | Non-spreading pestivirus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 15A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |